Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John G Matthews

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Drug Discovery Today|June 25, 2018
U-BIOPRED: evaluation of the value of a public-private partnership to industryJohn H Riley, Veit J Erpenbeck, John G Matthews, et al.
Pulmonary Pharmacology & Therapeutics|October 12, 2020
Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatabilityJohn Busby, Cecile Holweg, Akiko Chai, et al.
Pulmonary Pharmacology & Therapeutics|August 28, 2017
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthmaRui Zhu, Yanan Zheng, Nathanael L Dirks, et al.
Respiratory Medicine|February 8, 2018
Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroidsPhilip Korenblat, Edwin Kerwin, Igor Leshchenko, et al.
Thorax|April 4, 2019
Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label studyJohn Busby, Cecile T J Holweg, Akiko Chai, et al.
Clinical and Translational Allergy|July 18, 2022
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)Stanley J Szefler, Graham Roberts, Adalberto S Rubin, et al.
The New England Journal of Medicine|August 5, 2011
Lebrikizumab treatment in adults with asthmaJonathan Corren, Robert F Lemanske, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|September 13, 2016
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A Hanania, Phillip Korenblat, Kenneth R Chapman, et al.
Thorax|May 24, 2015
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studiesNicola A Hanania, Michael Noonan, Jonathan Corren, et al.
Science Translational Medicine|July 4, 2014
Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE productionGail M Gauvreau, Jeffrey M Harris, Louis-Philippe Boulet, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Drug Discovery Today|June 25, 2018
U-BIOPRED: evaluation of the value of a public-private partnership to industryJohn H Riley, Veit J Erpenbeck, John G Matthews, et al.
Pulmonary Pharmacology & Therapeutics|October 12, 2020
Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatabilityJohn Busby, Cecile Holweg, Akiko Chai, et al.
Pulmonary Pharmacology & Therapeutics|August 28, 2017
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthmaRui Zhu, Yanan Zheng, Nathanael L Dirks, et al.
Respiratory Medicine|February 8, 2018
Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroidsPhilip Korenblat, Edwin Kerwin, Igor Leshchenko, et al.
Thorax|April 4, 2019
Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label studyJohn Busby, Cecile T J Holweg, Akiko Chai, et al.
Clinical and Translational Allergy|July 18, 2022
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)Stanley J Szefler, Graham Roberts, Adalberto S Rubin, et al.
The New England Journal of Medicine|August 5, 2011
Lebrikizumab treatment in adults with asthmaJonathan Corren, Robert F Lemanske, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|September 13, 2016
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A Hanania, Phillip Korenblat, Kenneth R Chapman, et al.
Thorax|May 24, 2015
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studiesNicola A Hanania, Michael Noonan, Jonathan Corren, et al.
Science Translational Medicine|July 4, 2014
Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE productionGail M Gauvreau, Jeffrey M Harris, Louis-Philippe Boulet, et al.
Pageof 3